Advertisement
Loading...

AB Science S.A.

ABSCFPNK
Healthcare
Drug Manufacturers - Specialty & Generic
$1.12
$0.00(0.00%)
U.S. Market is Open • 14:57
Advertisement

AB Science S.A. Fundamental Analysis

AB Science S.A. (ABSCF) shows moderate financial fundamentals with a PE ratio of -45.11, profit margin of -1.33%, and ROE of 7.00%. The company generates $0.0B in annual revenue with strong year-over-year growth of 10.52%.

Key Strengths

Cash Position12.42%
PEG Ratio-0.71

Areas of Concern

ROE7.00%
Operating Margin-2.94%
Current Ratio0.96
We analyze ABSCF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -54.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-54.9/100

We analyze ABSCF's fundamental strength across five key dimensions:

Efficiency Score

Weak

ABSCF struggles to generate sufficient returns from assets.

ROA > 10%
-6.36%

Valuation Score

Excellent

ABSCF trades at attractive valuation levels.

PE < 25
-45.11
PEG Ratio < 2
-0.71

Growth Score

Excellent

ABSCF delivers strong and consistent growth momentum.

Revenue Growth > 5%
10.52%
EPS Growth > 10%
25.85%

Financial Health Score

Moderate

ABSCF shows balanced financial health with some risks.

Debt/Equity < 1
-0.25
Current Ratio > 1
0.96

Profitability Score

Weak

ABSCF struggles to sustain strong margins.

ROE > 15%
7.00%
Net Margin ≥ 15%
-1.33%
Positive Free Cash Flow
No

Key Financial Metrics

Is ABSCF Expensive or Cheap?

P/E Ratio

ABSCF trades at -45.11 times earnings. This suggests potential undervaluation.

-45.11

PEG Ratio

When adjusting for growth, ABSCF's PEG of -0.71 indicates potential undervaluation.

-0.71

Price to Book

The market values AB Science S.A. at -4.09 times its book value. This may indicate undervaluation.

-4.09

EV/EBITDA

Enterprise value stands at -76.17 times EBITDA. This is generally considered low.

-76.17

How Well Does ABSCF Make Money?

Net Profit Margin

For every $100 in sales, AB Science S.A. keeps $-1.33 as profit after all expenses.

-1.33%

Operating Margin

Core operations generate -2.94 in profit for every $100 in revenue, before interest and taxes.

-2.94%

ROE

Management delivers $7.00 in profit for every $100 of shareholder equity.

7.00%

ROA

AB Science S.A. generates $-6.36 in profit for every $100 in assets, demonstrating efficient asset deployment.

-6.36%

Following the Money - Real Cash Generation

Operating Cash Flow

AB Science S.A. generates limited operating cash flow of $-4.09M, signaling weaker underlying cash strength.

$-4.09M

Free Cash Flow

AB Science S.A. generates weak or negative free cash flow of $-4.36M, restricting financial flexibility.

$-4.36M

FCF Per Share

Each share generates $-0.06 in free cash annually.

$-0.06

FCF Yield

ABSCF converts -6.82% of its market value into free cash.

-6.82%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-45.11

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.71

vs 25 benchmark

P/B Ratio

Price to book value ratio

-4.09

vs 25 benchmark

P/S Ratio

Price to sales ratio

57.15

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.25

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.96

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.07

vs 25 benchmark

ROA

Return on assets percentage

-0.06

vs 25 benchmark

ROCE

Return on capital employed

-0.36

vs 25 benchmark

How ABSCF Stacks Against Its Sector Peers

MetricABSCF ValueSector AveragePerformance
P/E Ratio-45.1129.35 Better (Cheaper)
ROE7.00%705.00% Weak
Net Margin-132.77%-53441.00% (disorted) Weak
Debt/Equity-0.250.39 Strong (Low Leverage)
Current Ratio0.964.01 Weak Liquidity
ROA-6.36%-19815.00% (disorted) Weak

ABSCF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews AB Science S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-49.54%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

73.37%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

102.56%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ